Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;19(5):762-767.
doi: 10.1016/j.jcf.2019.11.007. Epub 2019 Nov 21.

Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy

Alex H Gifford  1 , Nicole Mayer-Hamblett  2 , Kelsie Pearson  3 , David P Nichols  4
Affiliations

Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy

Alex H Gifford et al. J Cyst Fibros. 2020 Sep.

Abstract

Background: We recognize an unprecedented opportunity to study the effects of withdrawing one or more chronic treatments in people with CF (PwCF) who benefit greatly from CFTR modulator therapy, but feasibility and acceptance of such a study within the community is unknown.

Methods: We surveyed PwCF, their families, and their acquaintances between November 16, 2018, and December 2, 2018, and CF clinicians between December 19, 2018, and January 2, 2019, about treatment withdrawal research. We sought feedback from these groups about their level of interest in this research, the consistency with which they were taking modulator and non-modulator treatments, the ways in which they conceptualized health changes, and what chronic non-modulator treatments they were most interested in stopping. We also asked for stakeholder perspectives on the design of a treatment withdrawal trial, but we intend to report these perspectives elsewhere.

Results: Eighty percent (541/675) of CF community respondents and 95% (206/218) of CF clinicians said that a trial of treatment simplification should be performed in the context of highly effective modulator therapy. Most current CFTR modulator users (292/359, 81%) have not stopped another chronic treatment. Worsening lung function by spirometry or increased daily symptoms were important health indicators. PwCF, their families, and/or their acquaintances ranked airway clearance techniques and inhaled antibiotics as the most burdensome treatments.

Conclusions: There is considerable support among the CF community and CF clinicians in the U.S. for controlled trials to assess the safety and impact of treatment simplification in patients taking highly effective modulator therapy.

Keywords: Cystic fibrosis; Modulator; Survey; Treatment burden; Withdrawal study.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement Dr. Alex H. Gifford has received grant funding from the Cystic Fibrosis Foundation. Dr. Nicole Mayer-Hamblett has no conflicts of interest to declare. Ms. Kelsie Pearson has no conflicts of interest to declare. Dr. David P. Nichols has received grant funding from the Cystic Fibrosis Foundation.

Figures

Fig. 1.
Fig. 1.
Proportions of CF community members in the United States that ranked six chronic treatments with respect to perceived burden.
Fig. 2.
Fig. 2.
Proportions of CF community respondents in the United States who ranked six contingencies with respect to how helpful they are as indicators of health deterioration.
Fig. 3.
Fig. 3.
Proportions of CF clinicians in the United States who ranked six contingencies with respect to how helpful they are as indicators of health deterioration in people with CF (PwCF).
See this image and copyright information in PMC

References

    1. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. The New England journal of medicine. 2011;365:1663–72. - PMC - PubMed
    1. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. The New England journal of medicine. 2015;373:220–31. - PMC - PubMed
    1. Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. The New England journal of medicine. 2017;377:2013–23. - PubMed
    1. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. American journal of respiratory and critical care medicine. 2014;190:175–84. - PMC - PubMed
    1. Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, et al. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. American journal of respiratory and critical care medicine. 2017;195:1617–28. - PMC - PubMed

Publication types